title: Future technology insight: mass spectrometry imaging as a tool in drug research and development.
abstract: In pharmaceutical research, understanding the biodistribution, accumulation and metabolism of drugs in tissue plays a key role during drug discovery and development. In particular, information regarding pharmacokinetics, pharmacodynamics and transport properties of compounds in tissues is crucial during early screening. Historically, the abundance and distribution of drugs have been assessed by well-established techniques such as quantitative whole-body autoradiography (WBA) or tissue homogenization with LC/MS analysis. However, WBA does not distinguish active drug from its metabolites and LC/MS, while highly sensitive, does not report spatial distribution. Mass spectrometry imaging (MSI) can discriminate drug and its metabolites and endogenous compounds, while simultaneously reporting their distribution. MSI data are influencing drug development and currently used in investigational studies in areas such as compound toxicity. In in vivo studies MSI results may soon be used to support new drug regulatory applications, although clinical trial MSI data will take longer to be validated for incorporation into submissions. We review the current and future applications of MSI, focussing on applications for drug discovery and development, with examples to highlight the impact of this promising technique in early drug screening. Recent sample preparation and analysis methods that enable effective MSI, including quantitative analysis of drugs from tissue sections will be summarized and key aspects of methodological protocols to increase the effectiveness of MSI analysis for previously undetectable targets addressed. These examples highlight how MSI has become a powerful tool in drug research and development and offers great potential in streamlining the drug discovery process.
authors.affiliation: University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
authors.forename: D F
authors.initials: DF
authors.lastname: Cobice
authors.affiliation: Drug Metabolism and Distribution, Mass Spectrometry Imaging, AstraZeneca R&D, Macclesfield, UK.
authors.forename: R J A
authors.initials: RJ
authors.lastname: Goodwin
authors.affiliation: Biomolecular Imaging and Proteomics, National Center for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
authors.forename: P E
authors.initials: PE
authors.lastname: Andren
authors.affiliation: Biomolecular Imaging and Proteomics, National Center for Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
authors.forename: A
authors.initials: A
authors.lastname: Nilsson
authors.affiliation: SIRCAMS, School of Chemistry, University of Edinburgh, Edinburgh, UK.
authors.forename: C L
authors.initials: CL
authors.lastname: Mackay
authors.affiliation: University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.
authors.forename: R
authors.initials: R
authors.lastname: Andrew
mesh_terms: D000818:Animals; D003952:Diagnostic Imaging / Q000295:instrumentation / Q000379:methods; D055808:Drug Discovery; D006801:Humans; D013058:Mass Spectrometry / Q000295:instrumentation / Q000379:methods; D012106:Research